Target intelligence / Profile preview

FAM20B glycosaminoglycan xylosylkinase (FAM20B)

Target
FAM20B
Molecular classification
Enzyme, Secretory kinase, Glycan kinase
01

Overview

FAM20B glycosaminoglycan xylosylkinase (commonly known as FAM20B) is an atypical secretory kinase enzyme responsible for phosphorylating the xylose residue within the tetrasaccharide linkage region of proteoglycans in the Golgi apparatus[1][2][3]. This phosphorylation event acts as a molecular switch that is required for proper elongation and maturation of glycosaminoglycan (GAG) chains, including heparan sulfate and chondroitin sulfate[1][2][3]. FAM20B’s kinase activity is essential for the formation of the extracellular matrix and for cell–cell and cell–matrix communication[1][3]. It specifically enhances the catalytic activity of galactosyltransferase II (GalT-II), and loss of FAM20B or its activity leads to truncated proteoglycan linkages, defective GAG biosynthesis, and severe developmental abnormalities such as those seen in certain skeletal dysplasias and connective tissue disorders[1][2][3]. FAM20B is evolutionarily conserved and one of the only known animal cell kinases that directly modify glycans[3]. There are currently no known drugs that target FAM20B directly, nor are there established clinical biomarkers used for patient selection or efficacy monitoring of FAM20B modulation.

Other names
Family with sequence similarity 20, member BGlycosaminoglycan xylosylkinase (XYLK)FAM20B protein
02

Biological functions

Proteoglycan biosynthesisGlycosaminoglycan assemblyExtracellular matrix organizationRegulation of cell–cell and cell–matrix signaling
03

Disease associations

Skeletal dysplasia (e.g., Desbuquois dysplasia)Bone diseaseDisorders similar to Ehlers-Danlos syndrome
04

Safety considerations

Disruption of FAM20B activity results in impaired glycosaminoglycan (GAG) synthesis, leading to profound defects in embryonic development and skeletal formation[1][2].Loss of function is associated with developmental disorders and mimics Ehlers-Danlos–like syndromes[1][2].

Beyond the preview

Go deeper on FAM20B glycosaminoglycan xylosylkinase (FAM20B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAM20B glycosaminoglycan xylosylkinase (FAM20B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call